Necrosis News and Research

RSS
Mitomycin C offers limited benefit in reducing unsightly scars

Mitomycin C offers limited benefit in reducing unsightly scars

Common enzyme acts as a natural brake to prevent potentially deadly runaway inflammation

Common enzyme acts as a natural brake to prevent potentially deadly runaway inflammation

Phase 1 clinical trial of new anticancer drug from Human Genome Sciences

Phase 1 clinical trial of new anticancer drug from Human Genome Sciences

Enzymes from king crab are an effective treatment for scalds, sores, and trophic ulcers

Enzymes from king crab are an effective treatment for scalds, sores, and trophic ulcers

Results from study of Rituxan in rheumatoid arthritis show promise

Results from study of Rituxan in rheumatoid arthritis show promise

Remicade shows improvement in both the arthritis and psoriasis associated with psoriatic arthritis

Remicade shows improvement in both the arthritis and psoriasis associated with psoriatic arthritis

Discovery could pave the way to smallpox Immunity

Discovery could pave the way to smallpox Immunity

Breakthrough could help protect against the use of smallpox by terrorists

Breakthrough could help protect against the use of smallpox by terrorists

3 or 4 glasses of wine a week can kill cancer cells

3 or 4 glasses of wine a week can kill cancer cells

WHO reports likely Ebola case in Sudan

WHO reports likely Ebola case in Sudan

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

500,000 patients have now been treated with REMICADE® worldwide

500,000 patients have now been treated with REMICADE® worldwide

Functional genomics provide improved drug discovery

Functional genomics provide improved drug discovery

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology

DakoCytomation has acquired exclusive worldwide rights to develop and commercialize pharmacogenomic diagnostic tests in the field of oncology

New Research Information on Tumor Necrosis Therapy

New Research Information on Tumor Necrosis Therapy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.